RBF Capital’s Teva Pharmaceuticals TEVA Stock Holding History

RBF Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$678K	Hold	20,000	–	–	0.03%	357
2026 Q1	$602K	Sell	20,000 -30,000	-60%	-$965K	0.03%	350
2025 Q4	$1.56M	Hold	50,000	–	–	0.07%	233
2025 Q3	$1.01M	Hold	50,000	–	–	0.05%	315
2025 Q2	$838K	Hold	50,000	–	–	0.04%	339
2025 Q1	$769K	Hold	50,000	–	–	0.05%	329
2024 Q4	$1.1M	Sell	50,000 -40,000	-44%	-$728K	0.06%	279
2024 Q3	$1.62M	Hold	90,000	–	–	0.08%	231
2024 Q2	$1.46M	Sell	90,000 -10,000	-10%	-$154K	0.08%	220
2024 Q1	$1.41M	Buy	+100,000	New	+$1.26M	0.08%	245
2022 Q4	–	Sell	-70,000	Closed	-$565K	–	581
2022 Q3	$565K	Buy	+70,000	New	+$619K	0.05%	313
2020 Q4	–	Sell	-40,000	Closed	-$360K	–	408
2020 Q3	$360K	Buy	+40,000	New	+$423K	0.04%	270

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

RBF Capital's TEVA Position: Q2 2026 in Review

RBF Capital held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 20,000 shares worth $678K. The position accounts for 0.03% of the portfolio, ranked #357.

RBF Capital first reported a position in TEVA in Q3 2020 and has held it in 12 quarters since. The position peaked at $1.62M in Q3 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

RBF Capital held 20,000 shares of Teva Pharmaceuticals worth $678K as of Q2 2026.
RBF Capital left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.03% of RBF Capital's portfolio in Q2 2026, its #357 holding.
RBF Capital first reported a position in Teva Pharmaceuticals in Q3 2020 and has held it in 12 quarters since.
RBF Capital's Teva Pharmaceuticals position peaked at $1.62M in Q3 2024.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.